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Abstract. Recent years have seen tremendous progress towards therapy of many previously incurable neuromuscular diseases.
This new context has acted as a driving force for the development of novel non-invasive outcome measures. These can be
organized in three main categories: functional tools, fluid biomarkers and imagery. In the latest category, nuclear magnetic
resonance imaging (NMRI) offers a considerable range of possibilities for the characterization of skeletal muscle composition,
function and metabolism. Nowadays, three NMR outcome measures are frequently integrated in clinical research protocols.
They are: 1/ the muscle cross sectional area or volume, 2/ the percentage of intramuscular fat and 3/ the muscle water T2, which
quantity muscle trophicity, chronic fatty degenerative changes and oedema (or more broadly, “disease activity”), respectively.
A fourth biomarker, the contractile tissue volume is easily derived from the first two ones. The fat fraction maps most often
acquired with Dixon sequences have proven their capability to detect small changes in muscle composition and have repeatedly
shown superior sensitivity over standard functional evaluation. This outcome measure will more than likely be the first of the
series to be validated as an endpoint by regulatory agencies. The versatility of contrast generated by NMR has opened many
additional possibilities for characterization of the skeletal muscle and will result in the proposal of more NMR biomarkers.
Ultra-short TE (UTE) sequences, late gadolinium enhancement and NMR elastography are being investigated as candidates
to evaluate skeletal muscle interstitial fibrosis. Many options exist to measure muscle perfusion and oxygenation by NMR.
Diffusion NMR as well as texture analysis algorithms could generate complementary information on muscle organization at
microscopic and mesoscopic scales, respectively. 31P NMR spectroscopy is the reference technique to assess muscle energetics
non-invasively during and after exercise. In dystrophic muscle, 31P NMR spectrum at rest is profoundly perturbed, and
several resonances inform on cell membrane integrity. Considerable efforts are being directed towards acceleration of image
acquisitions using a variety of approaches, from the extraction of fat content and water T2 maps from one single acquisition
to partial matrices acquisition schemes. Spectacular decreases in examination time are expected in the near future. They will
reinforce the attractiveness of NMR outcome measures and will further facilitate their integration in clinical research trials.
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LIST OF ACRONYMS
NMR nuclear magnetic resonance
NMRI nuclear magnetic resonance
imaging
UTE Ultra-short TE sequences
CT computed tomography
EMA European Medicines Agency
FDA U.S. Food and Drug
Administration
DMD Duchenne muscular dystrophy
GRMD Golden retriever muscular
dystrophy
T1w, T2w, DWI T1, T2 and diffusion weighted
NMR images
TR, TE repetition and echo times
IDEAL Iterative Decomposition of water
and fat with Echo Asymmetry and
Least-square estimation NMRI
sequence
CPMG Carr-Purcell-Meiboom-Gill
sequence
EPG Extended Phase Graphs
B1 or B1+, B0 Radio-frequency transmit and main
magnetic fields
WMS World Muscle Society
BMD Becker muscular dystrophy
ISIS Image-selected in vivo
spectroscopy
ASL arterial spin labeling
BOLD blood oxygen level dependent
COST European Cooperation in Science
and Technology
SSFP Steady state free precession
IR-bSSFP inversion recovery balanced SSFP
TESS triple echo steady state
THE MOTIVATION FOR USING NMR AS
AN OUTCOME MEASURE IN
NEURO-MUSCULAR DISORDERS
The medical approach to neuro-muscular diseases
has radically changed during the last two decades or
so. A majority of these diseases is of genetic ori-
gin and were so far impossible to cure. Treatments
were essentially supportive and palliative. With no
exception, they are rare disorders. This fact con-
tributed to their confinement far aside from the main
avenues of research of the pharmaceutical industry.
Rare diseases are now receiving full attention, with
major structural programs launched and funded by
public institutions at a multi-national level. And,
more important than any other consideration, the
progress of gene therapy and pharmacogenetics has
or is about to revolutionize the course of many of
these diseases [7, 23, 32, 33, 45, 62, 76, 174, 184,
217, 248, 256].
Because of these innovative therapies, new needs
have emerged over a relatively short period of time,
with the necessity to monitor muscle response to
interventions. To this end, novel tools had to be devel-
oped. In an ideal world, they should be non-invasive,
quantitative, cost effective and generate results that
are simple to interpret. They can be grouped in 3
main categories: the functional tools, the biologi-
cal fluid biomarkers and the imagery. The functional
tools occupy the foreground, with a variety of devices
and protocols, many optimized for the investigation
of specific movements, but also with others aiming
at a global evaluation of the patient activity [54, 109,
158, 167–169, 171, 191, 216, 218–220]. These ones
belong to a rapidly growing new discipline, named
actimetry, and offer the exclusive possibility to eval-
uate the patient in his personal environment over
extended periods of time. The biological fluids con-
stitute also a new class of biomarkers, with promising
results, in particular since the discovery and now
use of RNAs. Imaging, the third main player, is
increasingly being used as an outcome measure. It
requires expensive equipment, high-end ultrasound
devices making no exception to this. In addition,
tomographic methods, computed tomography (CT)
and nuclear magnetic resonance (NMR), suffer from
absence of portability. Nevertheless, NMR is the only
technique that can assess individual muscle anatomy,
composition and function in a single examination.
These unique properties are more and more largely
understood and appreciated at their exact value, as
illustrated by the imaging requirements issued by the
regulatory authorities, EMA and FDA, for new drug
registration.
With this review, the authors tried to offer a com-
prehensive overview of the data currently published
on the use of muscle NMR as an outcome mea-
sure, in actuality or as a potential tool for future
studies. Instead of listing studies in an objective but
impersonal mode, they chose deliberately to insert
comments and express opinions with the main goal of
guiding and helping readers who might have in mind
the introduction of quantitative imaging in their prac-
tice. The authors acknowledge the subjective nature
of parts of this review.
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QUANTITATION IS A PREREQUISITE TO
THE USE OF NMR AS A BIOMARKER
To be utilized as a biomarker [233, 250], any sur-
rogate indicator of disease or condition status must
be expressed as a quantified measure and demonstrate
its capacity to reflect specific pathological events with
accuracy and precision. To fulfill these requirements,
medical imaging had to go through a long evolution,
adding a quantitative dimension to the standard qual-
itative description of pathology. This was possible
thanks to a steady flow of technological innovation,
which has resulted in spectacular improvements in
hardware stability and versatility, and thanks also to
the patient and careful development of dedicated pro-
tocols [244]. This process, which has affected all
systems and organs, was no exception for muscle
imaging. For muscle disorders as for other ailments,
the benefits of quantitative imaging are multiple: a
better appreciation of disease severity, the possibility
to monitor pathological changes over time and, most
importantly, to evaluate skeletal muscle responses to
therapeutic intervention.
Similarly to what was achieved in most organs,
NMR has become a key-player for quantitative
imaging of the skeletal muscle [112]. Quanti-
tative variables and indices derived from NMR
imaging but also spectroscopy constitute the most
serious imaging candidates as biomarkers or out-
come measures in clinical trials focusing on muscle
pathology.
NMR OUTCOME MEASURES
CURRENTLY AVAILABLE
NMR imaging and spectroscopy can generate a
wealth of information on skeletal muscle anatomy,
structure and composition, physiology and biochem-
istry. While a great many NMR variables are being
tested and have their potential role as biomarkers
being investigated, only 3 NMR imaging outcome
measures are widely accepted, if not fully validated,
for skeletal muscle longitudinal monitoring. They are
almost systematically included in the setting of new
clinical trials. They aim at:
# evaluating muscle trophicity by measurements
of the muscle surface and volume,
# assessing the extent of chronic degenerative
changes in muscles by the percentage of fat sig-
nal infiltrating muscle,
Fig. 1. Skeletal muscle tissue characterization by NMR imag-
ing. Comparison of qualitative and quantitative approaches. CSA:
cross-sectional area; UTE: ultra-short echo time; DEMRI: delayed
enhancement MRI; Fat Sat: fat saturation.
# estimating disease activity with muscle water T2
relaxation time as an index in pathologies known
to be progressive.
SKELETAL MUSCLE TROPHICITY
Due to the combination of high spatial resolution,
good contrast, 3D capabilities, and efficient cor-
rection algorithms for source of distortions, mainly
gradient non-linearities, NMR imaging is the ref-
erence method for measuring organs volume and
dimensions [120, 125, 177, 277]. The statement
applies to skeletal muscle at least as much as to
other organs. Accuracy is seldom assessed because
it requires autopsy specimens but was excellent
when it could be performed [178]. Furthermore,
reproducibility and discriminant power have system-
atically been reported as very high [19, 80, 241, 257],
at least as good as with ultrasound [68] or computed
tomography [231] and with the advantage of superior
tissue characterization (see § below). The follow-
ing examples illustrate NMR capability to identify
subtle changes in muscle trophicity. After botulinic
toxin injection into a gastrocnemius muscle of chil-
dren with cerebral palsy, a 4% decrease in mass was
measured, compensated by an increase of 4% of the
soleus [268]. Forearm muscles volume determination
was repeated with coefficient of variation comprised
between 0.8 and 5.7% for the different muscles [227].
The effect of detraining after weeks of flow-restricted
concentric and eccentric exercise protocols were
evaluated, revealing different responses to detraining
depending on the training protocol [282].
In most instances, muscle trophicity rather than
volume is the variable of interest. When volumes
are determined, normalization to muscle length, and
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more often to adjacent bone length is performed in
order to obtain trophicity indices.
In diseased muscle, true muscle mass and not total
muscle volume is a preferred trophicity index. For
this reason, the contractile mass index is calculated as
the muscle volume (or cross-sectional area) × (1–fat
fraction), with the fat fraction taken from the water-fat
image analysis (see next §) [273].
In DMD boys, individual muscle contractile vol-
ume determination has revealed complex relation
with strength decrements. It was proportional to the
muscle loss in the quadriceps but it was found con-
siderably more important than expected from the
contractile tissue loss in the hamstrings and in the
tibialis anterior [273].
In normal muscle or when disease affects homoge-
neously the muscle, cross-sectional areas measured
at well-selected levels, f.i. mid-distance of the
thigh, will provide pertinent trophicity indices [110,
183, 234] while considerably shortening acquisition
and post-processing steps. However, this approach
implies rigorous positioning relative to anatomical
landmarks. These landmarks can be identified exter-
nally, such as the superior iliac spine or the upper
border of patella, or in scout scans acquired prior
to the actual measurement [81]. Preference is usu-
ally given to external landmarks because of possible
complexities in determining the scanner table posi-
tion when switching between coil configurations.
However, correction for slice mis-positioning on
successive exams is much easier when the bony struc-
tures have been entirely scanned. Better inter-scan
reproducibility of cross sectional area determination
has been reported with scout-image than with external
anatomical landmarks [81] When pattern of muscle
destruction by disease is known to be peculiar, f.i. pro-
gressing from proximal to distal or when it is simply
unknown, the acquisition of entire volumes or at least
thick stacks of slices spanning most of the muscle
length is highly preferable.
The pediatric population poses additional prob-
lems related to the growth process itself. On
examinations repeated at intervals allowing growth
effects to manifest, it is not easy to decide how slice
registration has to be adapted. For lack of better
solution, slice registration is usually adjusted in pro-
portion to the length increment. For 3D acquisitions,
it can be done during the data processing step. When
stacks of 2D slices are acquired, slice gaps have to be
increased also in proportion to the measured growth
and this is often skipped because it requires an inter-
vention at the time of the acquisition itself.
In practice, except for specific studies, thorough
evaluation of muscle trophicity has been very sel-
dom performed so far. It requires patient contouring
of each individual muscle that, to this date, has to be
performed manually. The task is long, tedious and lit-
tle rewarding, which explains why the evaluation of
muscle trophicity is most often left aside. Very few
longitudinal studies of muscle trophicity are avail-
able for neuromuscular patients. A positive effect
of enzyme replacement therapy on lower limb mus-
cle volume was observed in Pompe patients already
after 6 months of treatment [204]. After a one-year
observation period, calf muscle cross sectional area
of inclusion body myositis patients lost 6.5% while it
did not change in Charcot-Marie-Tooth 1A patients
[181]. In a small population sample, and using an
arguable methodology, no change in muscle trophic-
ity was detected in the lower limbs of spinal muscular
atrophy patients [228].
Attempts have been made to develop software for
automatic segmentation of muscle images. Very few
of the proposed solutions have been able to gener-
ate reliable results, and particularly no solution has
yet been successful when diseased, fatty infiltrated
muscles have to be analyzed. Very recently, a model-
based automatic segmentation software was reported
to generate results in close agreement with those
of manual segmentation [130]. The naive sugges-
tion has been made to determine global estimates of
muscle mass based on intensity histogram of entire
segments of limbs [166]. It would offer little advan-
tage over simple external measurements and ignores
the fact that usually not all muscles are affected
simultaneously by disease. In the thigh of GRMD
dogs, depending on the muscle considered, trophic-
ity estimated by the muscle volume normalized to
body mass was found to increase, stay normal, or
decrease with age [138]. Focusing attention on the
ones that are moderately to severely affected but not
destroyed will increase the capacity to detect inflex-
ion in disease progression whilst global measurement
by a dilution effect over less affected muscles would
decrease the capacity to detect changes. A more
realistic approach seems to turn to interactive soft-
ware solutions. Here, operator contribution remains
mandatory, but it is also the case in practice when
using automatic methods with the need to scroll
through the segmented volume to check for errors.
At least one of such software is under development
and is based on the random-walker algorithm [42].
With this method, the operator has just to strike
each muscle not on all but only every five to ten
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slides. In case contours are incorrectly detected by
the algorithm, the operator can immediately apply
a correction by another pencil strike in the erro-
neously assigned region. Tests performed on thigh
muscles show comparable results to manual segmen-
tation, in terms of muscle volume determination and
of inter-operator variability, with the advantage of a
processing time cut by a factor of ten at least. This
can be further accelerated by optimizing the software
reactivity to intervention, also possibly by injecting
some prior knowledge of muscle shapes and relative
positions.
The difficulty in segmenting muscle images and
the main raison for failure of automatic detection is
the frequent absence of visible muscle contours on
part of their circumference. This is particularly true
with standard T1w or T2w spin echo sequences. One
way to improve situation is to perform the segmen-
tation on images that present an improved contrast
between muscle tissue and fascia, as it is the case on
gradient echo images, acquired at specific echo times
when water and fat signals are in opposed phases (see
below). In our laboratory, trophicity measurements
are systematically performed on this type of images.
Attempts to further reinforce contrast of fascia and
aponeuroses, with dedicated susceptibility imaging
sequences, have so far been unsuccessful.
Another motivation for a fine assessment of muscle
trophicity is the frequent absence of fatty degenera-
tive changes in neuromuscular pediatric patients at
the first stage of disease. It has been hypothesized
by pediatric neurologists that relatively subtle alter-
ation of muscle trophicity might be an early indicator
of muscle involvement (Robert Carlier and Susana
Quijano-Roy, personal communication). It remains
to be proven and the availability of fast, user-friendly
segmentation methods will allow thorough testing of
this idea.
CHRONIC DEGENERATIVE CHANGES
Chronic damages to myocytes as well as long-
lasting fiber structural anomalies will at some
point result in contractile tissue replacement by fat
and/or connective tissue. Imaging of fibrosis remains
a challenging issue, which will be discussed in
another paragraph. To the contrary, fatty degenera-
tive changes are easily detected and quantified, taking
advantage of the differences in resonance frequencies
(chemical shift) and also possibly in T2, or even in T1,
relaxation rates between water and lipids hydrogen
components. For a comprehensive technical review,
read Bley et al. or Hu and Kan [24, 119].
Visual grading of fat infiltration on T1w spin
echo images, for example the Lamminen-Mercuri
scale [140], is satisfactory for muscle diagnostic pur-
poses but is absolutely inappropriate to monitor the
more subtle chronic degenerative changes progres-
sion. Supposing that the human eye would be good
enough to classify lesions between 1 and 4 without
error, which is certainly not the case, a change in
classification would happen on average for a 17.6%
increase in fat fraction. Even the most severe forms
of dystrophy do not achieve such an annual rate of
muscle destruction. Failure of Lamminen-Mercuri
grading to assess adult limb-girdle muscle dystrophy
type I progression was patent in the recent study of
Willis et al. It is sometimes proposed as a solution
to perform on the same screen a head to head com-
parison of series of T1w images acquired at different
points in time during follow up. Looking that way
at repeated series of images certainly helps to detect
changes but remains highly observer dependent, with
unknown sensitivity threshold and without the indis-
pensable quantitation needed to compare patients or
interventions. Trying to take advantage of the appar-
ent simplicity of the approach, attempts have been
made quite some time ago [148] and more recently
[166, 198] to separate water and fat by a threshold
applied to routine T1w images. Some earlier efforts
have tried to take into account the possible coexis-
tence of fat and water in the same voxel and have
calculated the fat fraction using a linear combina-
tion of pure fat and pure muscle signals [148]. The
latest studies have just operated a binary separation
between fat and muscle voxels, which is totally inad-
equate for the evaluation of fatty infiltrated muscles
in the context of chronic muscle diseases [166, 198].
All these approaches based on standard T1w image
analysis assume perfect or almost perfect transmitter
and receiver homogeneity, which is never the case.
It was possibly an acceptable postulate when it was
common to work with low field systems, 0.5T; it is not
the case anymore, and certainly wrong at high field,
3T and more, or when reception is made by multi-
ple arrays of surface coils. Until technical solutions
are found and implemented to guarantee very high
homogeneity of transmitter and receiver fields and/or
perfect post-processing corrections of imperfections,
one should discourage intensity-based separation of
muscle and fat, which is particularly misleading for
the non-experts who can be abused by the apparent
simplicity of the method.
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For the monitoring of muscle chronic degenera-
tive changes, preference is nowadays largely given to
water-fat imaging sequences, most often referred to
as Dixon sequences [159]. They take advantage of the
phase shift that progressively develops during the evo-
lution time of a gradient echo to separate the water and
fat resonances. The major advantage of this approach
is that the separation between water and fat is to the
second order independent of the main magnetic field
homogeneity and, as a consequence, extended fields
of view covering large volumes can be investigated.
In the standard Dixon version, only the methylene
resonance of lipids is considered and two or, better,
three images with fat and water successively in-phase
and out-of-phase are acquired and allow extraction of
the water and fat components. Two-point (extended)
Dixon may generate satisfactory results in the liver.
However, for muscle applications, swaps between
water and fat components can occur between limbs
or inside limb segments, the latter being considerably
more of a problem [112]. Three-point Dixon is almost
always immune to this issue.
Ignoring the other lipid resonances introduces
some degree of inaccuracy [271]. This can be
improved by a better modelling of the lipid spectrum,
usually 3 or 4 main resonances, which requires the
collection of 6 echoes and relatively intensive com-
putation [118]. This approach, known as Iterative
Decomposition of water and fat with Echo Asym-
metry and Least-square estimation (IDEAL) and
T2*-IDEAL, is currently the most advance method
for water-fat imaging. The multiple echo acquisition
implies relatively long echo collection and repeti-
tion time, with the need of T2* effect corrections.
The IDEAL method measures more accurately the
hydrogen fat fraction and has the potential to iden-
tify differences in the lipid spectrum, which might be
caused by nutrition or disease. There is little evidence
of this in the skeletal muscle, or if present, there are
likely to be of small amplitude and hardly detectable
in routine conditions.
If the relative intensities of the lipid spectrum
infiltrating the muscle can be considered as being
independent of the patient condition, which seems a
reasonable assumption, there is no need to go through
a 6-echo acquisition. A linear correction factor can be
applied to the fat signal and accurate fat fraction will
be obtained from standard 3-point measurement. The
correction factor was determined in our lab to be 1.82
[14].
How the muscle fat content is expressed can also
vary. One can simply look at the percentage of the
actual NMR signal in the voxel or in the muscle that
can be attributed to fat. Depending on the image repe-
tition time and echo times chosen, corrections for T1
and T2* effects can be applied. One can go further
and try to express the fat content as g of lipids per unit
muscle mass or volume. Such procedures have been
developed for the liver and require additional assump-
tions or measurements of the tissue lipid composition
[155].
As already stressed, consistency is key to success
in clinical trials. Simplicity is a vital factor to ensure
consistency. Bearing this in mind, at the time of this
writing, we recommend 3-point, 3D when possible,
Dixon, with proton density weighting (for example,
TR of 10 ms and flip angle of 3°) for water-fat imaging
of diseased muscle [112]. The standardized correc-
tion factor for lipid spectrum may or not be applied
and simple percentage of fat signal parametric maps
generated. Accuracy may be slightly affected but not
precision nor discriminant power, which is what mat-
ters in the context of longitudinal studies, with or
without intervention.
When intramuscular fat content is low, there is
no need to deploy convoluted hazardous processes
[12, 136]. Lipid detection can easily be sensitized
by shortening TR in 2D Dixon or increasing the flip
angle in 3D Dixon while exactitude of relative frac-
tion will be preserved by applying correction factors
for water saturation.
While water-fat separation based on chemical
shift differences is the accepted state-of-the-art
method to evaluate fatty infiltration of tissues, many
clinical groups are still measuring the muscle mono-
exponential T2 decay [83, 92, 134, 135, 267]. In
absence of mobile lipids in the tissue, an elevated T2
points towards inflammatory, oedematous changes.
The T2 increase due to inflammation or oedema rarely
exceeds 5 to 10 ms. But when fatty degenerative
changes are present, because of the much longer T2 of
lipids as compared to water, the mono-exponential fit
of T2 decay is largely driven by the degree of fat infil-
tration and the muscle global T2 becomes essentially
a measure of tissue lipid content [37], as demon-
strated by the tight correlation between global T2
and fat fraction calculated from Dixon images [14] or
lipid fraction measured by 1H localized spectroscopy
[135].
Either based on true water-fat separation or esti-
mated from global T2 changes, a large body of
evidence indicates that muscle chronic degenera-
tive changes can be very precisely assessed, disease
progression and response to therapy can be finely
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monitored. It has been demonstrated in a number of
neuro-muscular diseases.
In the thigh of Duchenne patients, average fat depo-
sition was reported to be 5%/year, with 50% of fat
total content being predictor of loss of ambulation
in the year to come [80]. In a small cohort of 3
adult Becker patients, thigh fatty infiltration rate was
measured at 3.7%/year [27]. Combining percentage
of fat maps with manual segmentation of muscle,
contractile cross-sectional areas were determined in
Duchenne patients [273]. Confrontation of percent-
age of fat maps with Lamminen grading showed a
systematic overestimation of the fatty degenerative
changes with the qualitative methods [271].
Forearm investigation revealed more severe
involvement of flexor than extensor muscles, and
a much faster progression of fatty infiltration in
non-ambulant than in ambulant Duchenne patients
[111, 263].
One year administration of corticosteroids to
young Duchenne boys stopped the fatty infiltration
process in the thighs and legs while fatty infiltration
rate was respectively of 7% and 3% in non-treated
children [10]. The severity of the disease allowed the
identification of fatty degenerative changes over 18
months, based only on T1-weighted signal intensity
measures, with the demonstration of inter-individual
and inter-muscle variability [113]. Such an imaging
approach is obsolete according to current standards of
quantitative imaging and cannot be recommended for
future investigation. The same method had been used
earlier, in combination with global T2 measurements,
to describe differential involvement of muscles in five
Duchenne patients [92].
A one-year follow up multi-centric study of
LGMDI patients unambiguously established the
superiority of quantitative water-fat imaging, pin-
pointing statistically significant fat content differ-
ences of 1 to 4% in lower limb muscles, whilst
Lamminen-Mercuri gradings did not detect any trend
and standard functional assessment fail to reach
statistical significance, to the exception of the res-
piratory function tests [269].
Quantitative water-fat imaging revealed a peculiar
bimodal distribution of fatty degenerative changes
across muscles of fascio-scapulo-humeral dystrophy
patients, as well as a distal to proximal progression
within affected muscles [123].
In oculo-pharyngeal muscular dystrophy patients,
lower limb fat content increased by 1.5% over 13
months, while it was unchanged in age-matched
control subjects [79]. Neither standard extensive
functional evaluation (MFM), nor visual grading did
show any change during the same observation period.
The high sensitivity of Dixon methods was demon-
strated in adult Pompe patients, most of them
presenting with a disease with much slower progres-
sion than dystrophinopathies. In the lower limb of
these patients, the average annual infiltration rate was
less than 1% but was detected with a high degree of
statistical significance [39].
Whole muscle fat fraction increased significantly
during the 12-month follow-up at calf level (1.2%)
but not thigh level (0.2%) in patients with Charcot-
Marie- Tooth disease 1A, and at calf level (2.6%) and
thigh level (3.3%) in patients with inclusion body
myositis [181].
In patients with rotator cuff lesions, quantitative
assessment of fatty degenerative changes more than
muscle atrophy in affected muscles showed a strong
relation with the extent of the muscle tears [185, 188].
It has also been reported in conditions affecting
secondarily the skeletal muscle.
In patients with amyotrophic lateral sclerosis, leg
global T2 measurements increased significantly over
a 4-month observation period, signing the progres-
sion of the fatty degenerative changes and was
correlated with the decline in foot dorsiflexion max-
imal voluntary isometric contraction [30].
While leg muscle total fat content was unaffected,
type 2 diabetic patients displayed a preferential dis-
tribution of lipids intramuscularly [127].
Whole-body Dixon identified an increased fat con-
tent in muscles of hyperkalemic periodic paralysis
[146].
Changes in skeletal muscle composition have been
systematically and consistently found in elderly sub-
jects, even though they are of limited amplitude until a
very advanced age. Percentage of intramuscular lipid
signal typically doubles, from 2 to 4%, between the
second and the seventh decade [3, 13, 46, 182, 214].
For its largest part, it represents a true increase in
muscle fat content and it only marginally reflects the
contractile tissue loss with aging [46].
In a diseased muscle, the intramuscular fat con-
tent can be seen as an integrator of the damages
sustained by the tissue over the patient life time,
which makes it a robust biomarker. One would then
like to use the increase or the levelling-off of fatty
infiltration over a defined period of time as a quan-
titative index of disease progression or response to
treatment. In muscle dystrophy, and particularly in
Duchenne boys, disease severity can be extremely
variable from one patient to another, which translates
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in annual fatty transformation rates ranging between
3 and 15+ percent [26, 80, 263]. This will seriously
complicate interpretation of any therapeutic interven-
tion. If a 5 percent increase in fat content is measured
after one year of treatment, does it have to be inter-
preted as a positive response in a particularly severely
affected patient or as a negative response in a mildly
affected patient? At a group level, one could obtain
the answer by conducting a standard placebo con-
trolled study. Such classical approach still would not
resolve the question at an individual level and raise
ethical consideration on delaying a potentially effec-
tive treatment in a group of patients suffering from a
deadly disease. One could also propose to use each
patient as its own control and, after an observation
period, determine if the slope of the fatty degenera-
tive progression abates after treatment is initiated. It
would allow to appreciate each patient’s response but
would cause the same ethical dilemma. Because the
intramuscular fat content is a cumulative index of all
damages to the muscle over the patient’s life span, it
is in itself a potent indicator of disease severity if the
age of the subjects is taken into consideration. At a
particular age, the higher the fat content, the higher
will be the anticipated fatty transformation rate.
Even though limited in number, forearm data from
the Genethon DMD natural history study support this
contention [262]. References tables could be built
by pooling all data collected in the different natural
history studies.
Along the same line, a strong correlation was
observed between the actual fat content in a muscle
and the annual intramuscular fat increase in a pop-
ulation sample of adult Pompe patients, who have
a relatively mild and homogenous disease course,
but also a scattered distribution of fatty degenerative
changes across the lower limb muscles [39].
The relation between fat fraction and its progres-
sion will inevitably plateau for high levels of fat
fraction. One cannot expect fact fraction to increase
by 15 percent when fatty replacement reaches 80%,
even though it was the case when it was only 40%.
A simple solution to circumvent the sigmoid relation
between fat fraction and its progression, is to normal-
ize the fatty replacement progression to the remaining
contractile fraction, i.e the true muscle transforma-
tion rate into fat. Taking the example above, the 15
percent fat increase when contractile tissue was 60
% would, if disease severity remains constant, corre-
spond to a 5% increase when contractile tissue was
down to 20%.
DISEASE “ACTIVITY”
More than two decades ago, animal studies have
identified that skeletal muscle tissue of mouse models
of muscular dystrophy had an elevated T2 [172, 235].
The same observation was made in a larger animal
model, the GRMD dog [238, 239, 260]. Interest-
ingly, muscle T2 normalized when gene therapy was
successful [190, 259, 283].
Recent reports have confirmed and expanded our
knowledge on the muscle T2 alterations in animals
with muscle dystrophy. Temporal changes of mus-
cle T2 was precisely determined in mdx mice with a
peak between 4 and 8 months of ages, then progres-
sively declining [104, 201, 254], T2 abnormalities
were described in other models of dystrophy [163,
252], with different patterns of intra-muscle distri-
butions in Large and in mdx mice. The particular
sensitivity of dystrophic muscle to eccentric exercise
was illustrated by the higher elevation of T2 in mdx
mice submitted to downhill running [165].
When response to micro-dystrophin gene expres-
sion was assessed in mdx mice, T2 mapping showed
superior discriminant capacity over magnetization
transfer ratio and diffusion tensor imaging [192].
Successful U7-exon skipping in GRMD dogs was
associated with a decrease in T2 of the treated limbs
[142]. Losartan treatment normalized muscle T2
of laminin deficient congenital muscular dystrophy
mice [252].
The T2 or the spin-spin relaxation time of muscle
water can be interpreted as an indicator of disease
activity in the skeletal muscle. Disease activity is a
purposively vague designation because a change in
T2 is a non-specific event that can be caused by many
mechanisms, inflammation, necrosis, muscle dystro-
phy, acute denervation, any circumstance that can
create an intracellular oedema, extracellular oedema
or a combination of both. This has been extensively
demonstrated in animals [31, 99, 101, 270] and in
humans. Physical exercise of moderate to high inten-
sity will increase muscle T2 through intra-myocytic
fluid accumulation in contracting myocytes. The pro-
cess is transient and should recess within hours as
opposed to pathological increases of T2. It is impor-
tant to realize that it may bias the evaluation of
patients if they are examined shortly after exercise.
For this reason, we recommend to perform imag-
ing before the functional evaluation studies, and this
particularly for patients with muscles fragilized by
disease.
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As mentioned in the previous section, animal mod-
els of muscle disorders in general do not develop
fatty degenerative changes that infiltrate their muscu-
lature and a global increase in muscle T2 as measured
via a mono-exponential fit to the NMR signal decay
will unambiguously indicate an increase in myocytic
water T2. In humans however, fatty replacement of
myocytes is a frequent outcome in chronic neuro-
muscular disorders. Since lipids have a much longer
T2 than intra-myocytic T2, a few percent of intra-
muscular fat content will push mono-exponential T2
up to values comparable to the ones measured in an
inflamed or damaged muscle tissue.
Many groups have measured the mono-exponential
T2 decay of fatty infiltrated muscles and have
reported that it was increasing with age in muscles
of Duchenne boys [9, 83, 92, 134, 135, 267]. Others,
to the contrary, have observed a decrease of mus-
cle T2 of Duchenne patients over time [83, 263], as
observed in animal models. These apparently con-
tradictory results can confuse the reader. In the first
instance, global T2 was determined and the increase
in T2 reflected the progression of the fatty degen-
erative changes. The information is redundant with
the one provided by Dixon sequences and results
obtained with the two techniques are tightly corre-
lated [14]. In the second case, muscle water T2 was
specifically measured and the progressive decrease
in T2 might either be related to growth since it can
be observed in normal subjects, at least in the dog
[238], or to the progressive exhaustion of the muscle
inflammatory and regenerative capacities.
For the sake of clarity, we advocate for the
use of precise denominations: muscle global T2,
whose alterations reflect mainly the fatty degenera-
tive changes and muscle water T2, which assesses the
involvement of the muscle tissue itself by the patho-
logical processes [37]. Because it mixes information
that can be obtained separately, we, and these are per-
sonal views of the writers, recommend to abandon
global T2 measurements of fatty infiltrated muscles.
It generates too much confusion, that can be avoided
by more elaborated analysis of the muscle T2 decay
(see below § on new developments).
The use of muscle water T2 as in indicator of
disease activity is not only possible in humans, it
is a highly relevant variable, at least as much as in
animal models. Water T2 is abnormally elevated in
muscles of Duchenne boys [9, 83, 263], but not in
Becker patients [274]. In late-onset Pompe patients,
Fig. 2. Failure of monoexponential fit of muscle T2 decay to distinguish between inflammatory and fatty degenerative changes. Both will
result in an increased skeletal muscle global T2. To separate inflammation from fatty infiltration, specific sequences (with fat saturation) or
processes (tri-exponential fit) need to be applied.
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Table 1
Key-features of global and water T2
Muscle T2 Global Water
Chemical origin water and fat water only
Responsive to slow, long term changes fast, short term changes
Indicative of mainly chronic fatty « disease activity »
degenerative changes
Methodological Dixon imaging requires optimized
issues to be preferred sequences or
processing tools
Explanation of the risk of confusion between detection of inflam-
mation and monitoring of fatty infiltration by T2 measurements.
water T2 was found moderately abnormal in approx-
imately one third of all muscles examined [39]. In
inflammatory myopathies, muscle T2, as a general
rule, is increased [161, 193, 279]. In diagnostic imag-
ing, this is classically detected using fat-saturated
(STIR) T2w sequences [55, 258]. In patients with
fascio-scapulo-humeral muscular dystrophy, a pro-
portion of muscles are STIR positive and have signs
of inflammation at biopsy [236]. However, with this
qualitative approach, one looks visually for contrast
between abnormal and normal muscles or areas. If
all muscles in a segment are inflamed, the examina-
tion will likely be considered falsely negative. Such
situation was encountered in juvenile dermatomyosi-
tis patients [38]. For this reason, and even if not
widely accepted by the medical community yet, we
systematically use quantitative water T2 maps for the
assessment of inflammatory myopathies, particularly
for the evaluation of the response to treatment.
Besides the lack of specificity of the muscle water
T2 changes, there remain uncertainties concerning
the exact temporal relation between the pathological
events and the T2 changes. It is unclear whether there
is a delay and how long it could be. Discrepancies
exist between muscle T2 and clinical status in some
patients with inflammatory myopathies. Natural fluc-
tuation of T2 in the course of muscular dystrophy is
not documented at all.
Interestingly, muscle water T2 can be found ele-
vated in some congenital myopathies, at least in
animal models of nebulin, ACTA1 or dynamin gene
mutations [93–95, 162]. This suggests that a certain
degree of cellular disorganization can affect intracel-
lular mobility enough to modify T2. The possibility of
abnormal muscle T2 in stable myopathies introduces
a restriction to the generalization of the use of muscle
water T2 as an absolute indicator of disease activity.
Also, muscle water T2 changes after denervation is
due to the relative increase in extracellular space that
accompanies the muscle tissue atrophy [82, 129, 199]
and reflects more the structural reorganization of the
muscle than disease activity stricto sensu.
It might then be wiser to restrain the use of muscle
water T2 for monitoring disease activity to conditions
known for being affected by destructive pathologi-
cal processes at least during certain periods of their
evolution. When it is the case, the determination of
muscle water T2 appears to be a powerful biomarker
of disease progression or response to intervention.
What was clearly demonstrated in animal models,
is now supported by several studies in humans. The
T2 level has been found to predict the progression
rate of the chronic degenerative changes. In young
Duchenne boys, after initiation of steroid treatment,
leg muscle T2 rapidly decreased by a few ms, this
reduction was maintained over time and was associ-
ated with a blockade of the fatty infiltration process
[10]. As already mentioned, in adult Pompe patients,
one third of all lower limb muscles investigated pre-
sented a mild to moderate elevation of water T2
in at least one of two scans at one year interval.
Those muscles experienced a faster progression of
the degenerative changes, approximately 35% faster,
than the muscles with normal T2 [39]. For the dif-
ferent muscles, there was a significant correlation
between mean T2 value and mean fat infiltration rate.
In patients suffering from fascio-scapulo humeral
dystrophy, it was shown that muscles with hyperin-
tensities on T2w images would subsequently display
significant fatty degenerative changes on later fol-
low up scans [84, 123]. Such observations are pivotal
in establishing the utility of muscle water T2 as a
biomarker of disease activity in neuromuscular dis-
eases.
Many questions remain to be addressed. One of the
most intriguing is the muscle water T2 response to
dystrophin expression in Duchenne patients already
under steroids. Steroids bring water T2 back close to
normal values and it is uncertain whether some degree
of dystrophin expression as obtained currently with
exon skipping will be able to further decrease T2.
Some preliminary observation suggests that it might
be difficult to detect (author’s personal observation).
Methodological issues make the exact determina-
tion of muscle water T2 challenging. We discussed
in detail the difficulties generated by fatty infiltration
and replacement. Full suppression of the lipid signal
is extremely challenging to obtain and residuals of
only a few percent will impact on the water T2 esti-
mate. Preference is nowadays given to methods that
do not attempt to minimize the lipid signal but rather
to separate the water and fat signals, based on chemi-
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cal shift or T2 differences, during the acquisition itself
or by subsequent processing. There are not many
and the most frequently used are based on multiple
spin-echo collection, in CPMG regime and cover-
ing a large range of echo-times. The Dixon water-fat
separation scheme has been incorporated in a multi
spin echo diagram, giving birth to the IDEAL-CPMG
sequence [122]. Another option is to perform a tri-
exponential fitting to the signal decay of a multi spin
echo sequence. Taking advantage of the large dif-
ference in T2 between water and fat, this method
was shown to efficiently separate the two components
[14]. Since this is obtained by post-processing exclu-
sively, and the sequence used is standard on most
NMR scanners, this approach can easily be imple-
mented in multi-center trials and this is actually the
case.
Accurate measurement of T2 is very demanding.
In a multi spin echo sequence, excitation and refo-
cusing pulses have to be exactly set tot 90◦ and 180◦.
Otherwise, the signal decay will be too fast, if effi-
cient gradient spoiling is available, which is rarely
the case on clinical systems, or too slow if unspoiled
signal arising from stimulated echoes adds to the spin
echo [112]. A practical approach has been to comple-
ment the multi TE spin echo sequence with another
sequence that maps the B1 field, and gives the exact
flip angle experienced by each voxel [280]. When
it departs from the prescribed value, the voxel in
question is withdrawn from the T2 map [14]. It is
simple, efficient, but eliminates a significant propor-
tion of voxels in areas of poor B1 homogeneity. Better
solutions exist and are in the process of being imple-
mented for clinical research studies. Instead of fitting
exponentials to the signal decay, models following a
more exact trajectory of both spin echoes and stim-
ulated echoes can be implemented and suppress the
need for B1 map. For example, the Extended Phase
Graphs (EPG) formalism is a powerful tool to depict
and understand the magnetization response of an arbi-
trary multi-pulse MR sequence, under different T1
and T2 relaxation constraints. Recently, Lebel and
Wilman have proposed to model the MSME signal
using the EPG formalism for precise T2 relaxometry
[143]. Rooney et al. have suggested that EPG model-
ing could be used to improve agreement and accuracy
of muscle T2 mapping across multiple sites [209].
Accuracy is important in clinical research but, what
counts most, is the discriminant power of a technique.
What is reassuring with water T2 measurements, is
that, even if the measurement is inaccurate because of
pollution by stimulated echoes, it remains sensitive
to the effect of pathologies and interventions. That
was the case in a clinical study where the measured
control T2 value was almost twice the real one, but
the effect of inflammation and its reversal by steroids
was nevertheless properly captured [161].
RELATIONS BETWEEN FUNCTIONAL
AND NMR OUTCOME MEASURES
A most frequent and recurrent question is the
relation between the standard functional outcome
measures for the skeletal muscle and the imaging
ones. When a clinical investigator is short of imagina-
tion, it seems to have become a favorite proposal: does
NMR correlate with function and to which extent?
The answer is always known in advance: yes, there
is a correlation between the two classes of tools, and
the correlation coefficient is typically around 0.7. It is
indeed obvious that muscle performance depends for
a significant part on muscle mass and composition. It
was already patent in early studies using qualitative
indices of fatty degenerative changes in Duchenne
patients [153]. This has been systematically con-
firmed [80, 91, 134, 246, 253, 273, 275]. Recent
additional evidence was obtained for myotonic dys-
trophy type I [106], Charcot-Marie-Tooth 1a and
inclusion-body myositis patients [181] as well as for
rotator cuff lesions [185] and aging [46]. Very logi-
cally, muscle strength correlates better with residual
contractile mass [273] than with the percentage of fat
infiltration [275].
An example of complementarity between imaging
and function is the use of the contractile cross sec-
tional area to determine whether a decreased muscle
strength or torque is due only to muscle hypotro-
phy and wasting or if intrinsic contractile defects
intervene. In Duchenne boys, the decreased muscle
strength remained abnormally low when normalized
for the remaining contractile tissue mass, pointing
to contraction anomalies of the dystrophic muscle
[253, 273].
There are other relevant questions. What is
the temporal relation between muscle composition
changes and the functional alterations? Data from
the Imaging-DMD consortium, presented at a WMS
meeting [255] but yet unpublished, showed that leg
muscles fat fractions increased up to 60% without
major impact on the 6 min walk test in DMD boys,
indicating that imaging changes might be a good
predictor of clinical prognosis. This is of utmost
importance and needs to be confirmed. Other studies,
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also in DMD patients, indicate, that decline in mus-
cle strength occurs in parallel with the progression of
fatty degenerative changes [253, 273], or might even
precedes them in the forearms [110].
Another important question is the discriminant
power of outcome measures. How do biomarkers
compare in terms of their capacity to detect the effect
of an intervention, for the smallest possible change
in the smallest population sample? Because they are
independent of subject’s volition, most NMR imaging
quantitative indices have superior reproducibility per-
formance and have been proposed as best candidates
to detect and monitor effect of therapy [26, 107]. This
conclusion relied on the assumption that therapeutic
agent will induce changes of identical amplitude for
all outcome measures, which is unlikely. The question
remains open but, even if not eliminated, the lesser
dependence of NMR outcome measures towards
patient’s collaboration constitutes a major asset.
Our enthusiasm must be tempered by the skepti-
cism opposed by the FDA to the use of NMR as an
outcome measure to assess the response of dystrophic
muscle to exon 51 skipping with drisapersen. The reg-
ulatory agency expressed concerns on the impact of
imaging platforms diversity, but also of differences
in imaging schemes and acquisition parameters, and
image analysis procedures on the estimated NMR
variables. There were also remarks on insufficient
quality control of system stability and assessment
of reproducibility. It was objected that the expected
effect of treatment might be on the same order as the
variability of the technique. Small sizes of popula-
tion samples were also criticized. Uncertainties on the
relation between NMR variables and functional mea-
surements were also stressed. Interestingly, there was
again some confusion in this report between global
muscle T2 and muscle water T2. The FDA request of
a complete harmonization of procedures across sites
is unrealistic from a technical standpoint. The only
way to reassure regulatory agencies on the value of
the NMR measurements will be the careful validation
of the processes that generate parametric maps and
the demonstration of the independence of the output
relative to differences in acquisition conditions.
A definitive advantage in favor of NMR would be
the identification of biomarkers that would be able to
predict the future clinical outcome very early on, and
before any functionally or anatomically detectable
response. In oncology, NMR spectroscopic indices
have been shown to reveal positive response to
treatment before any morphological sign of tumor
regression [147, 206, 221]. Similar markers have yet
to be identified for neuromuscular diseases. Muscle
phosphodiester level is a candidate for muscle dystro-
phy, where it is elevated in relation with the increased
membrane phospholipid turnover [69, 132, 262, 272],
and seems to respond very early on when dystrophin
is expressed [142].
There is a whole lot of reasons to pursue confronta-
tions between functional and imaging biomarkers
in patients with muscular disorders. As a general
rule, these are the discrepancies and the deviations
from tight correlations that should generate interest.
Unravelling their mechanisms will advance knowl-
edge whilst the contemplation of perfect agreement
is reassuring but is essentially sterile.
THE ROLE OF 31P NMR SPECTROSCOPY
AS AN OUTCOME MEASURE
In vivo NMR spectroscopy is a very powerful
tool to investigate skeletal muscle energy metabolism
non-invasively via 1H, 31P, 13C nuclei, to name the
most important ones [25]. 31P NMR spectroscopy
identifies and quantifies key energy metabolites,
phosphocreatine, ATP, inorganic phosphate [131].
It measures intracellular pH. Free cytosolic ADP
concentration and oxidative and non-oxidative ATP
production can be determined. With the relatively
simple use of surface coils positioned directly on
the segment of interest, it has generated a wealth of
invaluable information on skeletal muscle energetics,
its regulation during exercise and its disturbances by
diseases [8, 44, 102]. So far, NMR spectroscopy has
not played a significant role as an outcome measure in
neuro-muscular diseases, to the exception of muscle
dystrophy.
Years before dystrophin was identified and dys-
trophin mutations were recognized as the cause of
Duchenne muscular dystrophy, striking anomalies
were described in the 31P spectra of Duchenne boys
[44, 69, 187]. Interestingly, they are present at rest,
which notably facilitates their identification, and they
point towards anomalies at different subcellular lev-
els, the mitochondria, the contractile apparatus and
most importantly, the sarcoplasmic membrane [130,
247, 262, 284]. Total amount of P-compounds is low,
as a consequence of muscle atrophy and adiposity,
phosphocreatine/ATP is low, indicating a loss in con-
tractile tissue, inorganic phosphate/phosphocreatine
is elevated, reflecting higher ADP level at rest, which
in turn reveals a dysregulation of the mitochon-
drial oxidative phosphorylation control and/or an
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abnormal energy demand to maintain ionic home-
ostasis despite leaky cell membranes; intracellular
pH is alkaline, more precisely there is a prominent
pool of inorganic phosphate at a higher pH, coming
from damaged dystrophic cells and/or an expanded
interstitial compartment related to fibrosis [265]; last
but not least, the phospho-diester resonance, mainly
composed of glycerophosphocholine, is elevated, an
indicator of an accelerated membrane phospholipid
turnover in dystrophic myocytes.
Dynamic investigation of muscle energetics with
31P NMR seems to have never been performed in
DMD boys. In BMD and in DMD/BMD carriers,
anomalies of pH regulation during and after exercise
have been reported, however not pointing systemat-
ically in the same direction [16–18, 132, 247]. Both
increased or defective glycolytic activity has been
noted, while oxidative phosphorylation was most
often normal [132, 154, 246, 247]. Globally, exercise
results were considerably more scattered and did not
show the high degree of consistency observed at rest.
The severity of the 31P spectral anomalies at rest
has been shown to correlate with disease severity,
being already detectable in DMD female carriers,
present in Becker patients and patent in Duchenne
boys [132]. In the fingers flexors of DMD patients,
spectral anomalies were shown to be more intense in
non-ambulant than in ambulant patients and to relate
to the number of years after loss of ambulation [262].
In patients with fascio-scapulo-humeral dystrophy,
PCr/ATP ratio was found to decrease at the same time
as the muscle entered a phase of rapid destruction and
replacement by adipocytes [123].
Again in the fingers flexors of Duchenne patients,
the progression of these anomalies was monitored
over a one-year period and was significant in the
non-ambulant boys [110]. In the GRMD dogs, the
forelimbs treated by an adenovirus associated virus
mediated U7 exon-skipping, saw the elevated phos-
phodiester peak resume normal levels [142]. While
still relatively anecdotal, these observations strongly
suggest that 31P spectroscopy and in particular
the phosphodiester resonance may provide useful
biomarkers of dystrophic muscle response to dys-
trophin expression. Since 31P spectroscopy assesses
the sarcoplasmic membrane integrity and stability,
it will, by adding some degree of specificity, com-
plement the more global information given by fat
fraction and T2 maps. Very interestingly, PDE/ATP
was recently reported to be elevated in muscles of
BMD patients without any significant increase in fat
infiltration [272], suggesting that it might be a very
early biomarker of dystrophic processes, whilst water
T2 did not seem to be in the same population sample
[274].
NMR IMAGING OUTCOME MEASURES
IN DEVELOPMENT
Current developments are being pursued in two
directions
- either to identify NMR variables that would
reflect important histological, physiological or
biochemical changes that cannot be monitored
by current standard approaches, e.g., fibrosis,
microvascular dysregulation
- or to apply existing or novel NMR contrasts
to further characterize diseased skeletal muscle,
e.g., T1 or diffusion measurements.
Fibrosis
Replacement of striated skeletal muscle by connec-
tive tissue, mainly collagen, is the other main class
of degenerative change that affect muscles chroni-
cally damaged by disease [133, 137, 276]. More than
fatty infiltration, whose deleterious effect is indirect
through the associated loss in contractile tissue, fibro-
sis directly impacts on muscle function. Endomysial
fibrosis tightly correlates with loss of motor function
in Duchenne patients [56]. This is the justification of
the therapeutic research aiming at blocking or revers-
ing pathological deposits of connective tissues [288].
For the evaluation of efficacy of anti-fibrotic agents,
imaging biomarkers of fibrosis would be of consid-
erable help. Unfortunately, while fatty replacement
is easily imaged and quantified by NMR techniques,
it remains an unmet challenge to evaluate interstitial
fibrosis with NMR. The many proposals that have
been put forward to detect fibrosis by NMR essen-
tially indicate that none is so far entirely satisfactory.
Collagen and other macromolecules of the inter-
stitium but also their hydration water molecules have
very short T2s, in the range of 1 to a few hundred
s [70, 226]. On standard or fast imaging with TEs
of 1 to several ms, the NMR signal of these spins
is totally phased out and do not contribute to the
image. Dense connective tissue, like in tendons or
scars, appear as a signal void, readily detected on
routine imaging. Interstitial fibrosis ought to decrease
voxel signal intensity in proportion to the fractional
volume occupied. On standard images, these fluc-
tuations, which should typically be in the range of
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a few percent, appear to be hidden by the spatial
dependence of tissue NMR signal to voxel position
relative to arrays of surface receiver coils. Attempts
to correct for these, even though visually satisfactory,
have not so far permitted the quantification of the sig-
nal loss generated by connective tissue deposit. It may
tough contribute to the abnormal distribution of signal
intensities observed in muscles profoundly remod-
eled by disease, with fibrosis being most often an
essential component of this remodeling. Muscle sig-
nal heterogeneity, particularly on T2w images, is to
our knowledge a constant feature in dystrophic mus-
cle and likely reflects local fibrosis, to an extent that
remains difficult to determine at this moment [197,
238, 262].
Tissue T2 signal decay is a complex multi-
exponential process. When the T2 decay was sampled
at a very high rate, it was possible in animal models
to generate T2 spectra revealing a very short compo-
nent attributed to tissue macromolecules [210, 211].
When transposed to humans, the technique, known
ISIS-CPMG, identifies intra and extracellular com-
ponents but has so far failed to detect this very short
T2 pool of spins [6].
Magnetization transfer experiments are tailored to
study spin exchanges, either through dipole-dipole
interaction or true chemical exchange, between
mobile and semi-mobile pools of spins. Applied
to biological tissues, they measure exchanges rates
between free water and macromolecules, as well as
the relative sizes of these pools [104, 180]. In the past,
there were many attempts to relate magnetization
transfer contrast to tissue collagen content, particu-
larly in the liver, with mitigated results. Very recently,
fast imaging with optimized saturation schemes gen-
erated encouraging results, with a good correlation
between magnetization transfer contrast and fibrosis
in the liver [281]. Magnetization transfer contrast is
high in the skeletal muscle and its origin and mecha-
nisms have been studied by several groups in normal,
aging and diseased muscles, with a particular atten-
tion but yet poorly understood link to fibrosis [151,
152, 182, 214, 224, 225]. Particularly puzzling was
the unexpected negative correlation between mag-
netization transfer contrast and aging in a group
of normal subjects, however for one particular fre-
quency offset and irradiation power, whose results
cannot be extrapolated for other saturation conditions
[182]. The negative effect of fat infiltration on mag-
netization transfer was stressed [151]. Magnetization
transfer has been combined with double quantum fil-
tering and ultra-short TE (UTE) imaging in an attempt
to improve specificity towards collagen [72, 139].
Results are encouraging but must be regarded as pre-
liminary.
Quasi ignored until it became a most effective
and popular way to detect and quantify myocardial
fibrosis, the replacement of myocytes by connec-
tive tissue is accompanied by a parallel expansion of
the interstitial space. It can easily be quantified after
intravenous injection of a low molecular gadolinium
(Gd)-labelled contrast agent, like Gd-DTPA or Gd-
DOTA that rapidly diffuses in the interstitium, where
its concentration equilibrates with the plasma con-
centration. Minutes after injection, at the transient
pseudo-steady state phase of the Gd-contrast agent
distribution, the increase in the myocardium T1 relax-
ation rate relative to the increase in T1 relaxation rate
in the plasma, is a measure of the tissue fractional
extracellular volume [176, 179]. Though indirect, this
is a most powerful technique to quantify pathologi-
cal connective tissue deposit in the myocardium. A
prerequisite to the use of the method to quantify fibro-
sis is the absence of extracellular oedema or cellular
anomaly that may result in Gd contrast agent accu-
mulation or penetration into the myocytes, such as
necrosis, inflammation, dystrophy. In these instances,
or when they are suspected to co-occur with a struc-
tural remodeling, the volume of distribution of the Gd
contrast agent cannot be used anymore as a surrogate
marker of fibrosis.
The same method and principle might be applied
to evaluate indirectly interstitial fibrosis in the skele-
tal muscle but seems not to have been attempted yet.
Some difficulties may be expected in relation with
the lesser extracellular space of skeletal muscle, the
lesser degree of fibrosis usually in diseased muscles
and the lack of a blood reference signal as easily
available as in the ventricular cavity.
For the same reason, and because sodium con-
centration is more than 10 times higher in the
extracellular space than in the cells, global myocar-
dial Na concentration increases in case of fibrosis
and 23Na NMR imaging can be used to detect it
[116]. Because the evaluation is indirect and based on
changes devoid of specificity, the same reservations
as formulated for the gadolinium contrast agent apply
in case sodium concentration in tissues increases for
other reasons, with a list of confounding circum-
stances superimposable to the one for the Gd contrast
agents [160].
The NMR signal can be sensitized to motion
even at a sub-millimetric level and can be used to
track pressure wave propagation. In short, the speed
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of pressure wave propagation increases with tissue
stiffness. Hence, it can be used to estimate the visco-
elastic properties of a tissue [96]. This is the base
of NMR elastography, which is a validated method
to quantify liver fibrosis. The technique has been
transposed to the skeletal muscle and a number of cir-
cumstances have been evaluated [207]. The skeletal
muscle is a highly differentiated structure in a com-
plex environment. It does not seem trivial to relate
wave velocity exclusively to the underlying muscle
tissue from the same voxel. The whole environment
of contractile and non-contractile elements must con-
tribute and control the wave velocity at any particular
point in the muscle. In particular, the effect of fatty
deposits and infiltration is likely to be non-negligible.
The same holds for oedema and inflammation [170].
So, again specificity issues may arise. One also has
to keep in mind that tissue elastography can also be
evaluated using ultra-sound methods, with compa-
rable results and a clear advantage to ultrasound in
terms of implementation [63].
A more direct detection of fibrosis has been pro-
posed, which makes use of small peptides labelled
with Gd and having a high affinity for collagen
[35]. Results presented were convincing [36, 90]
but administration and toxicity issues will probably
restrict their use to animal models, this explaining the
very limited impact of this approach so far.
By far, the most promising way to image fibrosis is
the introduction of “ultra short TE” sequences, which
operate at a TE very close to 0 and are able to collect
the NMR signal of spins with a very short T2, of 1ms
and less [249]. These sequences have the potential
to visualize fibrosis directly, which would represent
a major advantage over all methods relying on indi-
rect link with fibrosis. The short T2 components can
be revealed either by direct subtraction of a standard
reference image with longer TE, dual band satura-
tion, adiabatic inversion [150] or better by extracting
the short T2 fraction from multi-exponential fitting
of multiple gradient echoes acquisitions covering a
range of TEs, with reconstruction of parametric maps
that correct not only for T2* decay effects but also
for lipids interferences [34, 261].
UTE imaging has been shown to reveal unam-
biguously cortical bones, deep layers of cartilages,
ligaments, tendons, aponeuroses [64, 65, 208]. Direct
demonstration of myocardial infarct scars has also
been demonstrated [50]. Visualization of skeletal
muscle connective tissue and attempts to quantify
it have been reported in normal subjects, in elderly
people and in myopathic patients [34, 46, 251]. Many
issues remain to be solved, in particular about the pos-
sible superimposition with fat signals components.
The greatest challenge, however, will be to isolate the
fraction of the short T2 molecules pool to attribute to
connective tissue. The same question holds for other
approaches, in particular for magnetization trans-
fer, with a significant part of the contrast generated
by contractile proteins. As already mentioned, the
combination of double quantum filtering, magneti-
zation transfer and UTE imaging might be a way to
extract more specifically the signal related to collagen
[72, 139].
Perfusion and oxygenation
Functional NMR imaging has established itself as
the gold standard for the non-invasive investigation
of brain physiopathology in neurological diseases but
also for cognitive studies in neurosciences [58, 189].
Very similar approaches have been developed and
successfully applied to the skeletal muscle [40, 195].
Tissue perfusion can be measured non-invasively
with a group of techniques called arterial spin label-
ing (ASL), that tag magnetically the arterial blood
upstream of the tissue of interest. This results in
a change in tissue magnetization proportional to
perfusion. Because ASL does not require any con-
trast agent injection, perfusion measurements can be
repeated very rapidly, every few seconds, and this
indefinitely [205, 212]. This is particularly advanta-
geous for the study of muscle perfusion, which can
vary over a range of 1 to 20 and more in dozen of sec-
onds. The ASL perfusion contrast to noise is low and
easily polluted by motion. Most ASL studies have
measured perfusion post-exercise or post-ischemia.
However, if a sacrifice on temporal resolution is
accepted, muscle perfusion at rest can be measured
if the ASL signal is averaged during a few minutes
[21, 40]. The BOLD (blood oxygen level dependent)
contrast [189], famous for its ability to detect brain
activation, can sense capillary and venous blood oxy-
genation in the skeletal muscle as well and provides
semi-quantitative estimates of blood oxygen satura-
tion [121, 124]. In contrast to most brain applications,
skeletal muscle BOLD contrast can be negative, in
case of deeper oxygen desaturation, as well as pos-
itive, when tissue oxygen extraction decreased [15,
48, 59, 144, 175]. Blood, and capillary blood vol-
ume impacts on the BOLD signal and complicates its
interpretation [67]. Muscle oxygen consumption can
be calculated, following Fick’s principle, as the prod-
uct of tissue perfusion times oxygen arterio-venous
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difference. Perfusion is determined with ASL while
large vessels oxygen content is derived from blood
T2 or susceptibility measurements [53, 73, 286].
Several conditions affecting the skeletal muscle
have been investigated by functional NMR, in par-
ticular acute and chronic ischemia [11, 74, 98, 145],
but also diabetes [287], systemic sclerosis [194] and
compartment syndrome [5].
With regard to neuromuscular diseases, the use of
functional NMR imaging has been so far very limited.
An unexpected contribution of muscle hypoperfusion
to the defective mitochondrial oxidative phosporyla-
tion in glycogenosis type 3 patients was identified
by combined dynamic functional and spectroscopic
NMR measurements [264].
Much more can be expected in the future. One
of the consequence of fibrosis when it also devel-
ops around arterioles is to encroach on vasodilation
reserve. In a study of leg muscles of hypertensive
animals, it has been shown that ASL can precisely
quantify this phenomenon [20]. Altered perfusion
is a pathological feature in Duchenne muscular
dystrophy [240], in part related to defective nitric
oxide production [117, 186], in part due to fibrotic
changes [137]. Having the possibility to measure
non-invasively in clinical research skeletal muscle
perfusion dynamics in Duchenne patients would be
of interest, in particular when it comes to assess the
efficacy of vasodilatory or anti-fibrotic drugs [23, 75,
288].
T1 – pre and post-gadolinium
Kinetics of T1 relaxivity changes after standard
low-molecular weight gadolinium contrast agent
injection can be processed in order to obtain quanti-
tative estimates of gadolinium contrast agent transfer
from the vascular space to the interstitium, or more
precisely to the accessible extravascular compartment
and the volume of this extravascular compartment
[141, 243, 245]. Ideally, the arterial input function
must be recorded at the same time as the tissue sig-
nal enhancement. In practice, it can reasonably be
assumed, which considerably facilitates data acqui-
sition. Ischemia, necrosis, inflammation, fibrosis can
nicely be evaluated from the associated changes in
gadolinium contrast agent transfer rate and volume
of distribution: slow rate and normal volume, slow
rate and expanded volume, fast rate and increased
volume, normal rate and increased volume, respec-
tively. In the canine model, the dystrophic muscle
is characterized by a parallel increase in gadolinium
transfer rate and volume of distribution, which mani-
fests by an increased peak enhancement with no shift
in enhancement timing [239].
Even though the injection procedure is minimally
invasive and perfectly safe, with the contrast agents
offering the highest stability, the method is losing
popularity. Despite the added value of the information
generated as compared to T2 mapping, it is nowadays
seldom implemented, because of the associated cost,
the acquisition time needed to sample the enhance-
ment curve adequately and the reluctance towards
injection of any sort to paediatric patients.
Prolonged remanence of albumin targeting
gadolinium contrast agent in dystrophic muscle of
mdx mice was a most promising way to characterize
membrane leakiness and myocytic damages [4, 232].
It remained confined to pre-clinical experimentation.
More recently, an interest has appeared for the
“pre-gadolinium”, probably better named the native
or the intrinsic T1 of skeletal muscle, which had long
been neglected on the ground that in the early days
of NMR imaging striated muscle had been shown to
be unchanged by inflammation or necrosis. In reality,
the methods of the time lacked sensitivity. The native
or intrinsic T1 of dystrophic muscle was shown to be
moderately but significantly elevated in GRMD dogs
[238]. Dilated and hypertrophic cardiomyopathies
display increased native T1, which seems to reflect
more myocardial cell damages than interstitial fibro-
sis [49, 85, 108]. The observation is corroborated by
the T1 shortening measured in collagen gels (Cal-
das de Araujo, personal communication). These leads
have to be further explored before a clear role can
be attributed to intrinsic T1 for the characterization
of the skeletal muscle. There is reasonable room for
optimism because of the robustness and speed of T1
measurement on modern scanners.
Diffusion
Diffusion weighted imaging (DWI) has been
widely applied in various medical and non-medical
fields since its first description by Stejskal and Tanner
in 1965 [229], ranging from solid material, phan-
tom and animal experiments to human tissue studies.
The ability to assess displacement of water pro-
tons in vitro and in vivo using diffusion-sensitizing
pulsed-field gradients has motivated its use to probe
microstructural information beyond the resolution
of conventional NMR imaging, i.e. in the range of
several microns. Depending on the pulsed-field diffu-
sion gradient scheme and strategy for analysis of the
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acquired DWI data, different parameters can be esti-
mated from the investigated object: the apparent dif-
fusion coefficient and the directional diffusivity, the
displacement probability, the sizes of the diffusion-
restricting boundaries (e.g. pore or cell diameter),
and the transition probability between compartments
delimited by semi-permeable boundaries.
It is about two decades ago that DWI has started
to be applied to investigate the skeletal muscle. The
vast majority of studies conducted in muscle tis-
sue were based on single-shot, diffusion-weighted
echo-planar imaging pulse sequences. For encod-
ing the diffusion process, mainly mono- or bi-polar
diffusion gradients in a spin-echo sequence type
were used. Only few studies have been conducted
in skeletal muscle using a stimulated-echo sequence
type. There are also several challenges to cope with
when applying DWI to skeletal muscle: in order to
get reproducible and reliable diffusion parameters, a
robust fat suppression needs to be achieved. While
most available techniques (spectral selective fat sup-
pression, inversion recovery based fat suppression)
suppress efficiently the main fat peak, the olefinic
fat peak close to the water peak contributes to dis-
turbing artefacts in DWI. Furthermore, DWI lacks a
high signal-to-noise ratio due to the fat suppression
method, the application of diffusion-sensitizing gra-
dients, and relatively long echo times (TE) compared
to the short T2 relaxation time of muscle water pro-
tons. Many of the DWI sequence parameters have an
important influence on the results, which has led to
a wide range of reported values of the different DWI
parameters.
Despite these technical particularities, potentially
interesting quantitative parameters from DWI might
emerge as new outcome measurements in skeletal
muscle pathology, as many of these parameters cor-
relate to structural muscle properties not accessible
using other NMR techniques. Apparent diffusion
coefficient, fractional anisotropy, and directions of
the main eigenvector can be calculated in a straight
forward manner from the diffusion tensor on a voxel-
by-voxel basis, and have been reported in several
studies in lower and upper extremities and trunk
[86, 215, 278]. Especially the assessment of mus-
cle fiber orientation using diffusion tensor imaging
has been reported to correlate well with the expected
muscle architecture [47, 86, 128]. Using more elab-
orate mathematical models to predict the diffusion
process assessed by NMR muscle fiber size and dif-
fusion properties of boundaries have been evaluated
as well [222, 223]. The robustness of DWI param-
eters in skeletal muscle has also been addressed
recently by optimizing DWI sequence parameters
and post-processing procedures for more reliable
repeat measurements and DWI parameter calculation
[87, 89, 100] Depending on the diffusion encoding
scheme, parameters correlating with perfusion and
microvasculature in skeletal muscle can be assessed
as well [78, 129].
While most studies of DWI in skeletal muscle
were conducted in healthy volunteers, DWI has also
been applied in few muscle pathologies [200, 203,
222, 223, 285] to assess DWI derived quantitative
parameters as biomarkers or outcome measures. The
apparent diffusion coefficient has repeatedly been
shown to be elevated in inflammatory myopathies,
with inconsistent results on the fractional anisotropy
[1, 88]. However, longitudinal assessment of dis-
ease activity and treatment response have not been
reported yet. In a study of Duchenne muscular dys-
trophy, DWI parameters correlated with clinical and
other NMR biomarkers of disease severity [200],
however, no clear additional value of the DWI param-
eters over the other NMR biomarkers were reported,
nor a longitudinal assessment in respect to disease
progression. The changes in diffusion coefficient and
in fractional anisotropy in the Duchenne patients
reflected mainly the degree of fatty infiltration. In
another recent study, also in Duchenne boys, where
the effects of fat and signal-to-noise were taken into
account, this time, an increase in diffusion coefficient
and in the eigenvalue, λ3, was revealed but only in
the tibialis anterior [115]. In a murine model of mus-
cular dystrophy, genetic treatment effects have been
monitored by multi-parametric NMR, including DWI
parameters [192]. However, the added value of DWI
to other NMR parameters were not assessed in this
study. In the opinion of the authors, a possible future
application of DWI as biomarker or outcome measure
seems to be promising in early stages of disease by
addressing statistically the disturbance of normally
ordered muscle fiber architecture.
Image texture
Image texture analysis is a research field on its
own, a niche for specialists with little impact so far
on muscle tissue characterization in diseases. Muscle
fat fraction and T2 changes are sensitive biomarkers
but very much non-specific in terms of the relation
to the underlying disease or disease mechanism. It
is conceivable that subtle patterns of signal intensity
distribution in particular muscles contain additional
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information that the human eye cannot perceive and
texture analysis algorithms might reveal.
In a dystrophic muscle, complex pathological
mechanisms take place, which result in a progressive
tissue disorganization. This loss of normal mus-
cle structure seems to be reflected by an abnormal
dispersion of muscle NMR signal intensities. Sig-
nal heterogeneity in a dystrophic muscle was first
noticed in the hypertrophied and failing myocardium
of a hamster model of gamma-sarcoglycanopathy
[196]. Larger than normal muscle signal fluctuations
revealed by an increased coefficient of variation may
be viewed as a zero order texture anomaly, with a ran-
dom spatial distribution. Similar observations were
reported in the skeletal muscle of GRMD dogs [238]
and of Duchenne boys [9, 262]. As mentioned earlier,
they may at least in part reflect muscle fibrosis which
is a significant component of the dystrophic mus-
cle disorganization. To a much lesser extent, normal
aging is associated to a small but significant increase
in skeletal muscle signal heterogeneity [13], which
suggests that this index may be a sensitive one. Inter-
estingly, T2w imaging combined with simple texture
analysis algorithms was able to discriminate muscle
dystrophies linked to different gene mutations in mice
models [163].
Muscle images of patients with centronuclear
congenital myopathies seem to present a particu-
lar texture, already detected at visual inspection
(R.Y Carlier, personal communication). A work-
ing group has been constituted within the European
Cooperation in Science and Technology (COST)
action MyoMRI (www.myo-mri.eu), with the spe-
cific objective of identifying abnormal patterns of
texture that may possibly be present in dystrophic and
congenital myopathies. Positive results have already
been obtained with images of GRMD dogs [43, 149].
In this study it was shown that co-occurrence matrices
are more effective descriptors of local texture in com-
parison to features based on momentums, run-length
matrices or local anisotropy. Similar results could be
found in other trials on NMR image texture analysis
[29]. It should be noted that co-occurrence matrices
are sensitive to the number and volume in voxels of
samples. This aspect was quite an issue in the above-
mentioned study. The added value of texture analysis
to the characterization of skeletal muscles anomalies
over time has to be determined.
An obstacle to the use of texture analysis in
multi-center trials is the extreme dependency of the
texture results on acquisition parameters and platform
specificities. Let just mention the impact of the image
spatial resolution on texture that will appear radically
different depending on the voxel size: if too large, tex-
ture might simply be wiped out, if too small, noise
level might obscure the underlying texture. Rigorous
control and harmonization of acquisition parameters
will be a requisite to any future use of texture analysis
as an outcome measure.
RECENT TECHNICAL DEVELOPMENTS
AND THEIR IMPACT ON THE USE OF
NMR AS OUTCOME MEASURE
Muscle imaging, and NMR imaging in particu-
lar, is increasingly used as an outcome measure.
It still constitutes a relatively young discipline cer-
tainly offering a great potential but with a need
to grow, and this in several directions. Broadening
the range of tools available to further characterize
normal and diseased muscles is one of the priority
and several of the main options were discussed in
the previous paragraphs. Developing protocols ded-
icated to the investigation of specific muscles, in
particular targets located deep in tissues, will also
gain importance. Very little has yet been proposed
to evaluate diaphragm structure and composition
in vivo [237]. Anatomical conformation as well as
respiratory motion make diaphragm investigation
challenging but its functional role and implication
in numerous diseases justify efforts [173]. Another
example among many others is the cell therapy for
oculo-pharyngeal muscular dystrophy patients [197],
with an interest to perform high resolution imag-
ing of laryngeal muscles injected with homologous
myoblasts and monitor, if not directly the fate of
the grafted cells, at least the possible impact on the
degenerative changes progression.
The wealth of additional information on muscle
structure and function that NMR will provide in
future, and is already largely able to provide, and
the multiple anatomical sites to investigate create a
major problem, the time required to perform these
advanced investigation. The issue is both economi-
cal, the examination cost, and practical and ethical,
the patient compliance to scans lasting more than one
hour. The latter is of course a major concern with
pediatric patients. To minimize this problem, a great
deal of efforts has been devoted and will continue
1/ to speed up image acquisitions, 2/ to collect sev-
eral NMR variables, and potentially biomarkers, in
one acquisition. The two approaches can in many
instances be combined.
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Faster acquisitions
To speed up acquisitions, parallel imaging makes
uses of the spatial information captured by arrays of
receiver coils to allow for a decrease in the number
of line acquisitions, with a proportional reduction in
acquisition time. Various schemes of parallel imaging
have been proposed almost two decades ago [57, 97,
202], are frequently but yet not systematically imple-
mented. More recently, but already one decade ago,
a new concept was introduced, known as compressed
sensing [60, 157]. The idea is to take advantage
of either spatial or temporal redundancies in some
representations of the underlying target, and of the
incoherence of the artifacts created by non-regular
sampling, in order to skip a large part of the acquisi-
tion matrix but still reconstruct images with a minimal
loss in quality. Application to muscle Dixon imag-
ing was recently demonstrated including in Becker
patients with acceleration factors up to 6 as com-
pared to standard imaging schemes [114, 156]. When
combined with non-Cartesian acquisition, like radial
sampling, acceleration factor of 10 and more can be
obtained with almost no penalty on image quality
[77].
More specifically about water T2 mapping, novel
acquisitions which are based on steady-state free
precession (SSFP) sequences, have been recently pro-
posed [22, 51, 106]. One of these approaches is based
on the partially spoiled steady state free precession
technique proposed by Bieri et al. [22]. This method
allows water-selective, fast 3D mapping of skeletal
muscle T2 and it can reasonably easily be installed
on commercial scanners [51]. A new fast T2 mapping
method using triple echo steady state (TESS) was
recently introduced to mitigate the intrinsic motion
sensitivity that generally accompanies all unbalanced
steady state methods, including T2-pSSFP [106].
TESS-T2 is not only free of the typical T1/T2 bias
common to all mono-parametric steady state meth-
ods, but also shows a high insensitivity to B1-field
inhomogeneities. Those novel methods are of course
compatible with parallel imaging and compressed
sensing.
Simultaneous acquisitions of variables
The concept of acquiring several NMR variables
of interest in a single sequence is not a novel one [28,
71, 242]. It was perhaps pushed to its limit with the
simultaneous collection of functional imaging, per-
fusion and oxygenation, and dynamic 1H and 31P
spectroscopy of skeletal muscle [66]. This approach
not only saved time but it allowed the combina-
tion of dynamic variables that would be illicit if
these variables had been acquired separately, this due
to far from perfect reproducibility of exercise bout
repetitions. It was subsequently shown that muscle
oxygen extraction can be derived from such multi-
parametric functional NMR protocols [41]. Such
multi-parametric tools identified abnormal perfusion
to contribute to the decreased oxidative phosphoryla-
tion capacity in glycogenosis type III patients [264].
For muscle characterization, simultaneous multi-
parametric mapping is a promising way to further
accelerate quantitative evaluations. Our team has
investigated the feasibility of fast (2 sec per imaging
slice) multi-parametric inversion recovery balanced
SSFP (IR-bSSFP) imaging, to track rapid physiolog-
ical adaptations in skeletal muscle during stress or
activation [52]. This sequence consists of an inver-
sion pulse followed by the acquisition of several
balanced SSFP images as the signal time course
approaches the steady state [213]. T1, T2 and M0
(relative proton density) can then be obtained from
a mono-exponential 3-parameter fit to the series of
images. IR-bSSFP time course signal can be more
accurately modeled by the Bloch Equations or by
the EPG formalism to take into account instrumental
errors (B1+ and B0 inhomogeneities, inversion effi-
ciency, non-ideal slice profile) [105, 163, 266] and
tissue composition (water/fat components).
Fat fraction and T2 maps are the two NMR imag-
ing biomarkers that are the most mature and appear
to be currently the most useful for muscle studies.
Collecting in one sequence the information needed
to generate both the fat fraction and the T2 maps will
represent a major leap forward.
A method called IDEAL-CPMG that combines
IDEAL algorithm with a Carr–Purcell–Meiboom
–Gill–sequence was recently proposed [120]. The
acquisition results in water and fat separated images
at each echo time. It then uses exponential fitting of
each signal decay for water T2 and fat T2 quantifi-
cation. Fat fractions are derived from fat and water
proton density images obtained using the IDEAL
reconstruction method. Nevertheless, non-ideal RF
pulse shape and RF field non-uniformity may lead
to the generation of stimulated echoes and ren-
der T2 determination highly unreliable using simple
exponential models. Moreover, the design of this
pulse sequence imposes using higher readout band-
width and consequently lowers the image signal to
noise ratio.
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Another approach to simultaneously measure
water T2 and fat fraction is to use multi-component
fitting of the standard MSME sequence by taking
advantage of the differences in T1 and T2 relaxivities
between fat and water protons. Exponential mod-
els can be used to describe the MSME signal decay
like in the work of Azzabou et al. [14]. Our team
recently proposed to use only the MSME sequence
and EPG-based fitting to simultaneously extract both
fat fraction and water T2 (Marty et al., NMR Biomed,
in press). Validation of this solution against standard
separate acquisitions is underway and will hopefully
justify its implementation in protocols with a cut in
acquisition time of approximately 50%.
CONCLUSIONS
Despite elevated costs, impossibility of bedside
operation, technological complexity and sometimes
challenging interpretation, NMR imaging and spec-
troscopy are progressively conquering a significant
role as outcome measures for muscle studies. The
role of imaging as an outcome measure in muscle
studies may still be perceived as lagging behind as
compared to the imaging contribution to the evalua-
tion of other organs, like the brain. This situation is
largely circumstantial, related to the lesser incidence
of muscle disorders, the poor availability of scanners
and the lack of therapeutic perspectives. The latter
two obstacles are gradually being lifted. Paramet-
ric maps of muscle fat fraction and of muscle water
T2 provide non-invasive and quantitative measures of
skeletal muscle degenerative changes and of disease
activity, respectively. They are by far the two NMR
biomarkers that are the most widely used in muscle
protocols. The perceived added value of such tissue
characterization has, despite the limitations and con-
straints listed above, has prompted the progressive
and now quasi systematic integration of NMR imag-
ing as an outcome measure in new therapeutic trials.
Current technical developments aim at shortening the
sequence acquisitions and at collecting the fat fraction
and T2 variables at once and will spectacularly reduce
the examination time. Their implementation in multi-
center trials can be expected in the next months and
years and will significantly improve the NMR exam-
ination acceptance by the patients, in particular the
pediatric ones. Alternatively, speeding up the acquisi-
tion of the fat fraction and T2 maps will free up time to
include the determination of other biomarkers in clin-
ical protocols, for instance, the phosphodiester level
by 31P spectroscopy, muscle perfusion with arterial
spin labeling and/or interstitial fibrosis with UTE
sequences. The capability to investigate skeletal mus-
cles, either superficially or profoundly located, and to
characterize muscle anatomy, structure, biochemistry
and function non-invasively and potentially simulta-
neously is unique to NMR. Thanks to the steady flow
of technological innovation, these properties shall be
more and more exploited even in a clinical context in
the near future and will reinforce the role of NMR as
an outcome measure in skeletal muscle clinical trials.
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